• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

    11/11/24 7:48:55 AM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email
    ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00
    Get the next $TLSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/6/25 6:09:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/31/25 5:54:39 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:15:05 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    See more
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

      TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

      9/26/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by TriSalus Life Sciences Inc.

      10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/15/25 7:54:52 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/15/25 7:34:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form D filed by TriSalus Life Sciences Inc.

      D - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/8/25 4:19:26 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TLSI
    Financials

    Live finance-specific insights

    See more

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lake Street initiated coverage on TriSalus Life Sciences

      Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

      2/13/25 8:48:50 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

      12/17/24 8:31:30 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

      ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

      11/11/24 7:48:55 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief Financial Officer Young James Emmett was granted 13,175 shares, increasing direct ownership by 36% to 49,663 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:37:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Research Cox Bryan F. was granted 15,722 shares and sold $24,678 worth of shares (4,764 units at $5.18), increasing direct ownership by 10% to 119,415 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:33:13 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Clinical Operations Devlin Jodi was granted 24,131 shares and sold $24,678 worth of shares (4,764 units at $5.18), increasing direct ownership by 58% to 52,764 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:31:57 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      12/4/24 4:00:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      10/21/24 8:25:05 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

      Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Support Strategic Vision TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and techn

      4/30/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care